These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Meredith RF Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435 [TBL] [Abstract][Full Text] [Related]
5. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Winter JN Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146 [TBL] [Abstract][Full Text] [Related]
7. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. Smith S; Sweetenham JW Future Oncol; 2007 Jun; 3(3):255-62. PubMed ID: 17547519 [TBL] [Abstract][Full Text] [Related]
8. Innovative strategies in lymphoma therapy. Jäger U Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Rao AV; Akabani G; Rizzieri DA Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070 [TBL] [Abstract][Full Text] [Related]
10. Does health economics have an impact on non-Hodgkin's lymphoma patients' options? Otte A Nucl Med Commun; 2008 Aug; 29(8):748-9. PubMed ID: 18753830 [No Abstract] [Full Text] [Related]
12. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Chatal JF Cancer Biother Radiopharm; 2006 Feb; 21(1):1-4. PubMed ID: 16480325 [No Abstract] [Full Text] [Related]
13. Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas. Lim SH; Marcus RE Blood Rev; 1992 Sep; 6(3):157-62. PubMed ID: 1422284 [TBL] [Abstract][Full Text] [Related]
16. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma. Apuri S; Sokol L Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526 [TBL] [Abstract][Full Text] [Related]
17. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk? Otte A; Dierckx RA Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349 [No Abstract] [Full Text] [Related]
18. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents. Pauwels EK; Erba P Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631 [TBL] [Abstract][Full Text] [Related]
19. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924 [No Abstract] [Full Text] [Related]
20. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas. Delmonte A; Ghielmini M; Sessa C Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]